Abbott ($ABT) Positive results from interferon-free phase 2 "Co-Pilot" study for the treatment of hepatitis presented by Abbott 

Thursday, April 19, 2012 at 7:51AM
DDE Editor in Hep C, abt

Abbott Labs (NYSE: ABT) says data from 'Co-Pilot,' found that more than 90% of patients new to HCV treatment achieved sustained viral response through 12 weeks.

• In a three-arm study known as 'Co-Pilot,' different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12-weeks post treatment (SVR12) in 95% and 93% of treatment-naive genotype 1 (GT1) patients, with no post-treatment relapses. In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.
• In addition, SVR12 was achieved in 47% of patients who were previous non-responders to past HCV treatment.
• Safety info – Arm 1 in Treatment-Naive Patients
  • There were no post-treatment relapses in these patients
  • One patient discontinued due to asymptomatic isolated ALT/AST elevations at week 2
• Safety info – Arm 2, Treatment-Naive Patients
  • There were no post-treatment relapses in these patients
  • One patient discontinued due to noncompliance in week 1

Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).